Harold H. Shlevin sold $151k of GALT
director at GALECTIN THERAPEUTICS INC. 30,000 shares at an average of $5.03, traded Jun 26, 2026, filed Jun 30, 2026.
Score components
- +15RoleDirector
- +11Trade size$151k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001133416-26-000061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | MOption exercise Common Stock10b5-1 | +7,732 | $1.23 | $9,510 | 14,232 | Jun 30, 2026 |
| Jun 26, 2026 | SOpen-market sale Common Stock10b5-1 | -7,732 | $5.00 | $39k | 6,500 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Common Stock10b5-1 | +22,268 | $1.23 | $27k | 28,768 | Jun 30, 2026 |
| Jun 29, 2026 | SOpen-market sale Common Stock10b5-1 | -22,268 | $5.04 | $112k | 6,500 | Jun 30, 2026 |
| Jun 26, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -7,732 | $0.00 | $0 | 52,268 | Jun 30, 2026 |
| Jun 29, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -22,268 | $0.00 | $0 | 30,000 | Jun 30, 2026 |
Related signals
Other insiders at GALECTIN THERAPEUTICS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $262k 52,037 shares | -2555% | |
| 8Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $24k 7,557 shares | -100% | |
| 0Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $1,761 568 shares | -100% | |
| 23Weak | GALTbuy GALECTIN THERAPEUTICS INC | Kary Eldred director | $810 300 shares | +0% | |
| 35Weak | GALECTIN THERAPEUTICS INC | Jack W Callicutt Chief Financial Officer | $233k 60,000 shares | -89% | |
| 28Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $232k 60,000 shares | -100% | |
| 19Weak | GALECTIN THERAPEUTICS INC | Joel Lewis President and CEO | $321k 84,000 shares | -9% | |
| 21Weak | GALECTIN THERAPEUTICS INC | Khurram Jamil Chief Medical Officer | $33k 8,125 shares | -100% | |
| 16Weak | GALECTIN THERAPEUTICS INC | Kary Eldred director | $2,611 700 shares | +1% | |
| 31Weak | GALECTIN THERAPEUTICS INC | Kary Eldred director | $2,611 700 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.